Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Theravance Breathing Easy: Once-Daily COPD Combo Expected To Meet Regulatory Standards

Executive Summary

With largely positive results from four of seven Phase III studies, GlaxoSmithKline and Theravance say they are on track for filing their LABA/LAMA combination UMEC/VI at the end of 2012. But some analysts are wary about regulatory prospects for any LABA-containing drugs and say concerns about dosing could trip up U.S. filing.

Advertisement

Related Content

GSK Anoro Ellipta Appears Poised For Smooth Advisory Panel; Is First LAMA/LABA On Horizon?
GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose
New COPD Candidates Could Get Hung Up On Safety Concerns
Business News, In Brief
New COPD Candidates Could Get Hung Up On Safety Concerns
Merck Continues Pursuit Of Cardiovascular Candidates With Theravance Partnership
Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer
Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
Relovair Data Raises Respiratory Stakes For GSK And Theravance
FDA Supersizes Its Order For LABA Safety Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel